User profiles for "author:A Agustí"

Antònia Agustí

Servei de Farmacologia Clínica. Hospital Universitari Vall d'Hebron. FICF. Universitat de …
Verified email at icf.uab.cat
Cited by 2700

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

J Vestbo, SS Hurd, AG Agustí, PW Jones… - American journal of …, 2013 - atsjournals.org
Chronic obstructive pulmonary disease (COPD) is a global health problem, and since 2001,
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published its strategy …

Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should)

A Agustí - Proceedings of the American Thoracic Society, 2007 - atsjournals.org
Chronic obstructive pulmonary disease (COPD) is associated with pulmonary and systemic
inflammation. The latter is likely to contribute significantly to the pathobiology of numerous …

An official American Thoracic Society/European Respiratory Society statement: research questions in chronic obstructive pulmonary disease

…, JA Wedzicha, KC Wilson, A Agustí… - American journal of …, 2015 - atsjournals.org
Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of
morbidity, mortality, and resource use worldwide. The goal of this Official American Thoracic …

[HTML][HTML] Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled …

…, D Lora, N Imaz-Ayo, LE Barón-Mira, A Agustí… - The Lancet, 2021 - thelancet.com
Background To date, no immunological data on COVID-19 heterologous vaccination
schedules in humans have been reported. We assessed the immunogenicity and …

[HTML][HTML] Lung-function trajectories leading to chronic obstructive pulmonary disease

P Lange, B Celli, A Agustí, G Boje Jensen… - … England Journal of …, 2015 - Mass Medical Soc
Background Chronic obstructive pulmonary disease (COPD) is thought to result from an
accelerated decline in forced expiratory volume in 1 second (FEV1) over time. Yet it is …

[HTML][HTML] Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype

A Agustí, LD Edwards, SI Rennard, W MacNee… - PloS one, 2012 - journals.plos.org
Background Because chronic obstructive pulmonary disease (COPD) is a heterogeneous
condition, the identification of specific clinical phenotypes is key to developing more effective …

The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort

R Kohansal, P Martinez-Camblor, A Agustí… - American journal of …, 2009 - atsjournals.org
Rationale: Understanding normal lung development and aging in health and disease, both
in men and in women, is essential to interpreting any therapeutic intervention. Objectives …

Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness: a randomized, controlled trial

F Barbé, LR Mayoralas, J Duran, JF Masa… - Annals of Internal …, 2001 - acpjournals.org
Background: The sleep apnea–hypopnea syndrome is defined by a pathologic number of
respiratory events during sleep (the apnea–hypopnea index, defined as the number of …

Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index

MA Puhan, J Garcia-Aymerich, M Frey, G ter Riet… - The Lancet, 2009 - thelancet.com
Background The BODE index (including body-mass index, airflow obstruction, dyspnoea,
and exercise capacity) was an important contribution to the prognostic assessment of …

Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease

…, E Silverman, J Vestbo, E Wouters, A Agustí… - American journal of …, 2012 - atsjournals.org
Rationale: Accurate prediction of mortality helps select patients for interventions aimed at
improving outcome. Objectives: Because chronic obstructive pulmonary disease is …